President Donald Trump is attempting to seize further control of funding decisions made by the National Institutes of Health. | President Donald Trump is attempting to seize further control of funding ...

China is aiming to account for at least 25% of first-in-class drugs as part of a five-year push to cement its emerging status as a hotbed for innovative R&D. | China is aiming to account for at least ...

Following Takeda’s historic approval of the first orexin agonist with its narcolepsy treatment Orzeyful, Alkermes has followed up with pioneering data that looks to take the hyped drug class out of ...

Telix has struck a deal to buy ITM Isotope Technologies Munich | Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to ...

A midstage study of Cue Biopharma’s hives drug candidate has hit its primary endpoint, emboldening the biotech to move the would-be challenger to Xolair into a phase 2b/3 trial.

Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go ...